Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trial
Alkomiet Hasan, Stefan Leucht, Astrid Roeh, Berthold Langguth, Maximilian Hansbauer, Tatiana Oviedo-Salcedo, Sophie K Greiner, Irina Papazova, Lisa Löhrs, Isabel Maurus, Wolfgang Strube, Moritz J Rossner, Michael C Wehr, Ingrid Bauer, Stephan Heres, Peter M Kreuzer, Stephanie Zimmermann, Thomas Schneider-Axmann, Thomas Görlitz, Anja Baumgartner, Susanne Karch, Silvia Egert-Schwender, Christiane Blankenstein, Philipp Rothe, Elias Wagner, Zahra Aminifarsani, Bryan Downie, Claudia Leucht, Peter Falkai · 2026
Read Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trial by Alkomiet Hasan, Stefan Leucht, Astrid Roeh, Berthold Langguth, Maximilian Hansbauer, Tatiana Oviedo-Salcedo, Sophie K Greiner, Irina Papazova, Lisa Löhrs, Isabel Maurus, Wolfgang Strube, Moritz J Rossner, Michael C Wehr, Ingrid Bauer, Stephan Heres, Peter M Kreuzer, Stephanie Zimmermann, Thomas Schneider-Axmann, Thomas Görlitz, Anja Baumgartner, Susanne Karch, Silvia Egert-Schwender, Christiane Blankenstein, Philipp Rothe, Elias Wagner, Zahra Aminifarsani, Bryan Downie, Claudia Leucht, Peter Falkai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13272664.txt.
Description
Alkomiet Hasan leads a 2026 randomised trial testing whether an old blood pressure drug, spironolactone, can help thinking in schizophrenia. Brain signaling through a pathway called NRG1-ERBB4 is linked to memory problems in this illness. Animal work suggested spironolactone can adjust that pathway, prompting a proof-of-concept trial.
Ninety patients were assigned to 100 milligrams, 200 milligrams, or a placebo for three weeks, with working memory as the main outcome. Memory scores improved most in the high-dose group, but the planned analysis did not show a clear win over placebo. Later checks hinted at a benefit, and both doses were well tolerated, supporting longer or higher-dose trials.
Catalog record
| CREATOR | Alkomiet Hasan, Stefan Leucht, Astrid Roeh, Berthold Langguth, Maximilian Hansbauer, Tatiana Oviedo-Salcedo, Sophie K Greiner, Irina Papazova, Lisa Löhrs, Isabel Maurus, Wolfgang Strube, Moritz J Rossner, Michael C Wehr, Ingrid Bauer, Stephan Heres, Peter M Kreuzer, Stephanie Zimmermann, Thomas Schneider-Axmann, Thomas Görlitz, Anja Baumgartner, Susanne Karch, Silvia Egert-Schwender, Christiane Blankenstein, Philipp Rothe, Elias Wagner, Zahra Aminifarsani, Bryan Downie, Claudia Leucht, Peter Falkai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48152 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |